Use of bisphosphonates and the risk of osteonecrosis among cancer patients: A systemic review and meta-analysis of the observational studies

Supportive Care in Cancer

Volumn 22, Issue 2, 2014, Pages 553-560

  Lee, Si Huei ^a,b   Chan, Rai Chi ^a,b   Chang, Shy Shin ^c,d   Tan, Yin Ling ^e   Chang, Kai Hsiang ^a   Lee, Matthew C ^f   Chang, Huai En ^b   Lee, Chien Chang ^g,h  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^f Medical Wisdom Consultants   (United States)

^g NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^h HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Bisphosphonate; Cancer; Meta analysis; Osteonecrosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID; NERIDRONIC ACID; OLPADRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

ARTICLE; BONE NECROSIS; BREAST CANCER; CANCER PATIENT; DRUG USE; HUMAN; INCIDENCE; JAW OSTEONECROSIS; LUNG CANCER; META ANALYSIS; MULTIPLE CANCER; MULTIPLE MYELOMA; OBSERVATIONAL STUDY; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; SYSTEMATIC REVIEW; CASE CONTROL STUDY; COHORT ANALYSIS; NEOPLASM; PATHOLOGY; REVIEW;

BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; BONE DENSITY CONSERVATION AGENTS; CASE-CONTROL STUDIES; COHORT STUDIES; DIPHOSPHONATES; HUMANS; NEOPLASMS;

EID: 84896052890     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-013-2017-y     Document Type: Article

References (31)

1. Zavras AI (2011) The impact of bisphosphonates on oral health: lessons from the past and opportunities for the future. Ann N Y Acad Sci 1218:55-61
2. Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115-1117
3. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62:527-534 (Pubitemid 38542516)
4. Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, Fenton R, Gahres N, Sausville E, Ord R, Meiller T (2006) Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 24:945-952 (Pubitemid 46638849)
5. Baillargeon J, Kuo YF, Lin YL, Wilkinson GS, Goodwin JS (2011) Osteonecrosis of the jaw in older osteoporosis patients treated with intravenous bisphosphonates. Ann Pharmacother 45:1199-1206
6. Barasch A, Cunha-Cruz J, Curro FA, Hujoel P, Sung AH, Vena D, Voinea-Griffin AE, Beadnell S, Craig RG, DeRouen T, Desaranayake A, Gilbert A, Gilbert GH, Goldberg K, Hauley R, Hashimoto M, Holmes J, Latzke B, Leroux B, Lindblad A, Richman J, Safford M, Ship J, Thompson VP, Williams OD, Yin W (2011) Risk factors for osteonecrosis of the jaws: a case-control study from the CONDOR dental PBRN. J Dent Res 90:439-444
7. Cartsos VM, Zhu S, Zavras AI (2008) Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people. J Am Dent Assoc 139:23-30
8. Cooper C, Steinbuch M, Stevenson R, Miday R, Watts NB (2010) The epidemiology of osteonecrosis: findings from the GPRD and THIN databases in the UK. Osteoporos Int 21:569-577
9. Etminan M, Aminzadeh K, Matthew IR, Brophy JM (2008) Use of oral bisphosphonates and the risk of aseptic osteonecrosis: a nested case-control study. J Rheumatol 35:691-695 (Pubitemid 351500068)
10. Fellows JL, Rindal DB, Barasch A, Gullion CM, Rush W, Pihlstrom DJ, Richman J (2011) ONJ in two dental practice-based research network regions. J Dent Res 90:433-438
11. Guarneri V, Miles D, Robert N, Dieras V, Glaspy J, Smith I, Thomssen C, Biganzoli L, Taran T, Conte P (2010) Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Canc Res Treat 122:181-188
12. Kallmes DF, Rad AE, Gray LA, McDonald RJ, Clarke BL (2009) Bisphosphonates are not associated with vertebral osteonecrosis. J Bone Miner Metabol 27:452-455
13. Pavkovic M, Petrushevska G, Jovanovic R, Karanfilski O, Cevreska L, Stankovic S, Stojanovic A (2010) Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphanates. Prilozi 31:39-49
14. Tennis P, Rothman KJ, Bohn RL, Tan H, Zavras A, Laskarides C, Calingaert B, Anthony MS (2012) Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis. Pharmacoepidemiol Drug Saf 21:810-817
15. Wessel JH, Dodson TB, Zavras AI (2008) Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. J Oral Maxillofac Surg 66:625-631 (Pubitemid 351381804)
16. Wilkinson GS, Kuo YF, Freeman JL, Goodwin JS (2007) Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis. J Natl Canc Inst 99:1016-1024 (Pubitemid 47240676)
17. Zavras AI, Zhu S (2006) Bisphosphonates are associated with increased risk for jaw surgery in medical claims data: is it osteonecrosis? J Oral Maxillofac Surg 64:917-923
18. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535
19. Lijmer JG, Bossuyt PM, Heisterkamp SH (2002) Exploring sources of heterogeneity in systematic reviews of diagnostic tests. Stat Med 21:1525-1537 (Pubitemid 34746061)
20. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control. Clin Trials 7:177-188 (Pubitemid 17189972)
21. Galbraith RF (1988) A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med 7:889-894
22. Song F, Khan KS, Dinnes J, Sutton AJ (2002) Asymmetric funnel plots and publication bias inmeta-analyses of diagnostic accuracy. Int J Epidemiol 31:88-95 (Pubitemid 34284907)
23. Filleul O, Crompot E, Saussez S (2010) Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases. J Cancer Res Clin Oncol 136:1117-1124
24. Allen MR, Burr DB (2009) The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg 67:61-70
25. Reid IR, Cornish J (2012) Epidemiology and pathogenesis of osteonecrosis of the jaw. Nat Rev Rheumatol 8:90-96
26. Favia G, Pilolli GP, Maiorano E (2009) Histologic and histomorphometric features of bisphosphonate-related osteonecrosis of the jaws: an analysis of 31 cases with confocal laser scanning microscopy. Bone 45:406-413
27. Hoefert S, Schmitz I, Tannapfel A, Eufinger H (2010) Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and nonsymptomatic osteonecrosis of the jaw based on scanning electron microscopy findings. Clin Oral Investig 14:271-284
28. Nicoletti P, Cartsos VM, Palaska PK, Shen Y, Floratos A, Zavras AI (2012) Genomewide pharmacogenetics of bisphosphonate-induced osteonecrosis of the jaw: the role of RBMS3. Oncologist 17:279-287
29. Kumar SK, Gorur A, Schaudinn C, Shuler CF, Costerton JW, Sedghizadeh PP (2010) The role of microbial biofilms in osteonecrosis of the jaw associated with bisphosphonate therapy. Curr Osteoporos Rep 8:40-48
30. Marx RE, Tursun R (2012) Suppurative osteomyelitis, bisphosphonate induced osteonecrosis, osteoradionecrosis: a blinded histopathologic comparison and its implications for the mechanism of each disease. Int J Oral Maxillofac Surg 41:283-289
31. Sedghizadeh PP, Kumar SK, Gorur A, Schaudinn C, Shuler CF, Costerton JW (2009) Microbial biofilms in osteomyelitis of the jaw and osteonecrosis of the jaw secondary to bisphosphonate therapy. J Am Dent Assoc 140:1259-1265